Table 1

Demographics, medications and disease activity for RA patients and controls

Clinical featuresEarly RA (N=22)Established RA (N=16)Healthy controls (N=22)
Age, years (median, range)52 (28–83)64 (39–80)48 (21–58)
Female:male15:79:719:3
Duration of RA, months (median, range)12 (2–23)174 (62–436)
Ethnicity: white (%)648186
Rheumatoid factor +ve (%)9181
Anti-CCP antibody +ve (%)9094
MedicationsNumber (%)Number (%)
NSAIDs16 (73%)5 (31%)
Methotrexate 5–20 mg/week17 (77%)11 (69%)
Sulphasalazine 1–3 g/day8 (36%)5 (31%)
Hydroxychloroquine 400 mg/day8 (36%)6 (37%)
Leflunomide 20 mg/day2 (9%)4 (25%)
Prednisone 2.5–10 mg/day12 (55%)3 (19%)
Adalimumab 40 mg/fortnight02 (12.5%)
Infliximab 5 mg/kg (8 weekly)01 (6.3%)
Rituximab 1000 mg × 2 every 6 months01 (6.3%)
Disease activityMedian (range)Median (range)
Tender joint count (68)3 (0–48)6.5 (0–17)
Swollen joint count (66)1 (0–14)2.5 (0–26)
Tender joint count (28)2 (0–14)2 (0–8)
Pain VAS (mm)19 (1–100)14.5 (2–23)
Global VAS (mm)16 (0–100)16 (2–49)
HAQ score0.25 (0–2.4)0.32 (0–2.25)
PF-SF-3670 (15–100)70 (0–85)
ESR (mm/h)*12 (1–53)12 (3–86)
CRP (mg/l)3.3 (1–27)3.8 (1–208)1 (1–15)
DAS28 – CRP3v2.76 (1.42–5.25)3.25 (1.79–4.59)
  • * Erythrocyte sedimentation rate (ESR) obtained in 21 early rheumatoid arthritis (RA) patients.

  • CCP, cyclic citrullinated peptide; DAS 28 – CRP3v, three variable disease activity score (tender and swollen joints, C-reactive protein); HAQ, health assessment questionnaire; NSAID, non-steroidal anti-inflammatory drug; PF-SF-36, physical function component of the short form 36 score; VAS, visual analogue scale.